title: Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer.
abstract: CXCR4 is a chemokine receptor implicated in the metastatic process. The CXCR4 ligand, CXCL12, was shown to bind also the CXCR7 receptor, a recently deorphanized chemokine receptor whose signalling pathway and function are still controversial. This study was conducted to determine patients clinic-pathological factors and outcome according to the expressions of CXCR4 and CXCR7 in renal cell carcinoma (RCC). CXCR4 and CXCR7 expression was evaluated in 223 RCC patients through immunohistochemistry; moreover CXCR4 and CXCR7 was detected in 49 others consecutive RCC patients trough RT- PCR. CXCR4 expression was low in 42/223 RCC (18.8%), intermediate in 71/223 (31.9%) and high in 110/223 (49.3%). CXCR7 expression was low in 44/223 RCC patients (19.8%), intermediate in 65/223 (29.1%) and high in 114/223 (51.1%). High CXCR4 and high CXCR7 expression predicted shorter disease free survival. In multivariate analysis, high CXCR4 expression (p= 0.0061), high CXCR7 (p= 0.0194) expression and the concomitant high expression of CXCR4 and CXCR7 (p= 0.0235) are independent prognosis factors. Through RT-PCR, CXCR4 was overexpressed in 36/49 and CXCR7 in 33/49 samples correlating with symptoms at diagnosis and lymph nodes status. So we can hypothesize that CXCR4 and CXCR7, singularly evaluated and in combination, are valuable prognostic factors in RCC patients.
authors.affiliation: Department of Oncological Immunology, National Cancer Institute, Naples, G. Pascale, Via Semmola, 80131 Naples, Italy.
authors.forename: C
authors.initials: C
authors.lastname: D'Alterio
authors.forename: C
authors.initials: C
authors.lastname: Consales
authors.forename: M
authors.initials: M
authors.lastname: Polimeno
authors.forename: R
authors.initials: R
authors.lastname: Franco
authors.forename: L
authors.initials: L
authors.lastname: Cindolo
authors.forename: L
authors.initials: L
authors.lastname: Portella
authors.forename: M
authors.initials: M
authors.lastname: Cioffi
authors.forename: R
authors.initials: R
authors.lastname: Calemma
authors.forename: L
authors.initials: L
authors.lastname: Marra
authors.forename: L
authors.initials: L
authors.lastname: Claudio
authors.forename: S
authors.initials: S
authors.lastname: Perdonà
authors.forename: S
authors.initials: S
authors.lastname: Pignata
authors.forename: G
authors.initials: G
authors.lastname: Facchini
authors.forename: G
authors.initials: G
authors.lastname: Cartenì
authors.forename: N
authors.initials: N
authors.lastname: Longo
authors.forename: L
authors.initials: L
authors.lastname: Pucci
authors.forename: A
authors.initials: A
authors.lastname: Ottaiano
authors.forename: S
authors.initials: S
authors.lastname: Costantini
authors.forename: G
authors.initials: G
authors.lastname: Castello
authors.forename: S
authors.initials: S
authors.lastname: Scala
mesh_terms: D000368:Aged; D000375:Aging; D002292:Carcinoma, Renal Cell / Q000175:diagnosis* / Q000378:metabolism* / Q000473:pathology / Q000556:secondary; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007668:Kidney / Q000378:metabolism / Q000473:pathology; D007680:Kidney Neoplasms / Q000175:diagnosis* / Q000378:metabolism* / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D012333:RNA, Messenger / Q000378:metabolism; D054387:Receptors, CXCR / Q000235:genetics / Q000378:metabolism*; D019718:Receptors, CXCR4 / Q000235:genetics / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016019:Survival Analysis
chemical_list: C501896:ACKR3 protein, human; C527276:CXCR4 protein, human; D012333:RNA, Messenger; D054387:Receptors, CXCR; D019718:Receptors, CXCR4